Calabasas-based Kythera Biopharmaceuticals, a developer of aesthetic medicine products, has added $10M more in new funding. The new funding came to light in this week's PricewaterhouseCoopers/NVCA MoneyTree report. No details on the funding have been announced by the company. Kythera is backed by ARCH Venture Partners, Prospect Venture Partners, Versant Ventures, Wilson Sonsini Goodrich & Rosati, Altitude Life Science Ventures, JAFCO, BBT/Apothecary Capital, and UCLA Venture Capital Fund. More information »